Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lodge

Showing results (471-480 of 485) with videos related to

Pageof 49
Sort By:
Journal of Medicinal Chemistry|June 26, 2009
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonistsRichard A Hartz, Vijay T Ahuja, Maria Rafalski, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with SchizophreniaDalton King, Christiana Iwuagwu, Jim Cook, et al.
ACS Chemical Neuroscience|October 18, 2016
Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of DepressionAndrew P Degnan, George O Tora, Hong Huang, et al.
Journal of Medicinal Chemistry|December 4, 2009
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonistRichard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, et al.
The Lancet. Respiratory Medicine|November 30, 2024
Associations between life-course FEV<sub>1</sub>/FVC trajectories and respiratory symptoms up to middle age: analysis of data from two prospective cohort studiesJennifer L Perret, Dinh S Bui, Carrie Pistenmaa, et al.
Bioorganic & Medicinal Chemistry Letters|September 27, 2012
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agentsJeffrey A Deskus, Douglas D Dischino, Ronald J Mattson, et al.
Annals of the American Thoracic Society|December 5, 2019
Lifetime Risk Factors for Pre- and Post-Bronchodilator Lung Function Decline. A Population-based StudyDinh S Bui, Jennifer L Perret, E Haydn Walters, et al.
Nature Communications|July 21, 2019
Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populationsRocío Rojo, Anna Raper, Derya D Ozdemir, et al.
The Lancet. Respiratory Medicine|April 10, 2018
Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of lifeDinh S Bui, Caroline J Lodge, John A Burgess, et al.
Schizophrenia Research|September 30, 2008
Summary of the 1st Schizophrenia International Research Society Conference oral sessions, Venice, Italy, June 21-25, 2008: the rapporteur reportsRoohi Abubaker, Maaike Alaerts, Ava-Ann Allman, et al.
Pageof 49

Showing results (471-480 of 485) with videos related to

Sort By:
Pageof 49
Journal of Medicinal Chemistry|June 26, 2009
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonistsRichard A Hartz, Vijay T Ahuja, Maria Rafalski, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with SchizophreniaDalton King, Christiana Iwuagwu, Jim Cook, et al.
ACS Chemical Neuroscience|October 18, 2016
Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of DepressionAndrew P Degnan, George O Tora, Hong Huang, et al.
Journal of Medicinal Chemistry|December 4, 2009
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonistRichard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, et al.
The Lancet. Respiratory Medicine|November 30, 2024
Associations between life-course FEV<sub>1</sub>/FVC trajectories and respiratory symptoms up to middle age: analysis of data from two prospective cohort studiesJennifer L Perret, Dinh S Bui, Carrie Pistenmaa, et al.
Bioorganic & Medicinal Chemistry Letters|September 27, 2012
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agentsJeffrey A Deskus, Douglas D Dischino, Ronald J Mattson, et al.
Annals of the American Thoracic Society|December 5, 2019
Lifetime Risk Factors for Pre- and Post-Bronchodilator Lung Function Decline. A Population-based StudyDinh S Bui, Jennifer L Perret, E Haydn Walters, et al.
Nature Communications|July 21, 2019
Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populationsRocío Rojo, Anna Raper, Derya D Ozdemir, et al.
The Lancet. Respiratory Medicine|April 10, 2018
Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of lifeDinh S Bui, Caroline J Lodge, John A Burgess, et al.
Schizophrenia Research|September 30, 2008
Summary of the 1st Schizophrenia International Research Society Conference oral sessions, Venice, Italy, June 21-25, 2008: the rapporteur reportsRoohi Abubaker, Maaike Alaerts, Ava-Ann Allman, et al.
Pageof 49